Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Q3 Preview: Zolgensma Back In The Spotlight

First sales of SMA gene therapy to be revealed

Oct 18 2019

• By Kevin Grogan

Novartis — Novartis sales in the spotlight on 22 October • Source: Shutterstock

Related Content

Sandoz Breaks Off Digital Deal With Pear

Oct 17 2019

Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line

Aug 27 2019

Novartis Battens Down Hatches Over Falsified Zolgensma Data

Aug 07 2019

Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation

Aug 14 2019

Novartis Eyes Fourth Approval For Cosentyx

Oct 02 2019

Novartis Ramps Up Digital Transformation With Microsoft AI Deal

Oct 01 2019

Label Battles: Beovu And Eylea Contest Begins In AMD

Oct 08 2019

Novartis Says SMA Baby Death Not Due To Zolgensma

Sep 19 2019

Related Companies

Novartis AG

AveXis, Inc.

Regeneron Pharmaceuticals, Inc.

Eli Lilly and Company

Pear Therapeutics, Inc.

Additional Topics

Sales & Earnings Commercial Strategy Gene Therapy Neurology Cancer BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window